To simplify, our research reveals that GPC2 promotes prostate cancer progression via MDK-mediated activation of PI3K/AKT signaling pathway, and GPC2 might be a potential therapeutic target in prostate cancer. This evidence concerns the gene AKT1 and Familial prostate cancer.